Indications for Unfractionated Heparin Drip in Pulmonary Embolism
Unfractionated heparin (UFH) drip is specifically indicated for high-risk pulmonary embolism with hemodynamic instability (shock or systolic blood pressure <90 mmHg), severe renal dysfunction (creatinine clearance <20-30 mL/min), extreme obesity, or high bleeding risk where rapid reversibility is needed. 1
High-Risk (Massive) Pulmonary Embolism
Hemodynamic instability is the primary indication for UFH drip over other anticoagulants:
- Patients presenting with shock, persistent hypotension (systolic BP <90 mmHg), or cardiogenic shock require immediate intravenous UFH 1
- UFH should be initiated without delay in high-risk PE, as LMWH and fondaparinux have not been adequately tested in hemodynamically unstable patients 1, 2
- The FDA approves UFH for both prophylaxis and treatment of pulmonary embolism 3
Dosing protocol for UFH in high-risk PE:
- Initial bolus: 5,000-10,000 units IV, followed by continuous infusion of 400-600 units/kg/day (approximately 30,000-40,000 units per 24 hours) 4, 3, 5
- Target aPTT: 1.5-2.5 times control value 1, 3
- Monitor aPTT every 4 hours initially, then at appropriate intervals 3
Severe Renal Dysfunction
- UFH is preferred when creatinine clearance is <20-30 mL/min, as LMWH and fondaparinux are contraindicated or require significant dose adjustment 1, 6
- UFH does not accumulate in renal failure and can be safely titrated to effect 1
High Bleeding Risk Requiring Rapid Reversibility
- UFH has a short half-life (60-90 minutes) and can be rapidly reversed with protamine sulfate 1
- Patients at elevated bleeding risk include those with recent surgery, recent hemorrhage, or active peptic ulcer disease 4, 7
- The ability to quickly discontinue and reverse UFH makes it preferable when bleeding risk is substantial 1
Extreme Obesity
- UFH is recommended over LMWH in patients with extreme obesity due to unpredictable pharmacokinetics of weight-based LMWH dosing 7
Initiation Before Diagnostic Confirmation
A critical indication is high or intermediate clinical probability of PE while awaiting diagnostic workup:
- Anticoagulation with heparin should be started immediately based on clinical suspicion before imaging confirmation 1, 4, 7
- The risk of delayed treatment outweighs the risk of unnecessary anticoagulation in patients with reasonable clinical suspicion 7
- This applies when diagnostic testing cannot be performed within 24 hours 1
When UFH is NOT Preferred (Use LMWH Instead)
For non-high-risk (hemodynamically stable) PE, LMWH or fondaparinux is preferred over UFH:
- LMWH is the recommended initial treatment for most hemodynamically stable patients with PE 1, 7, 2
- LMWH has equal or superior efficacy with lower bleeding risk compared to UFH 2, 6
- LMWH allows for fixed-dose subcutaneous administration without monitoring and potential outpatient management 8, 6
Absolute Contraindications to Heparin
Do not use UFH in the following situations:
- Active bleeding or recent hemorrhage 4, 7
- Acute stroke 7
- Current gastrointestinal bleeding 7
- Recent neurosurgery or ophthalmologic surgery 7
Monitoring Requirements
- Platelet count monitoring is mandatory due to risk of heparin-induced thrombocytopenia (HIT), especially if continued beyond 5 days 4
- Monitor hematocrit and occult blood in stool throughout therapy 3
- Weight-based dosing achieves therapeutic levels more quickly than fixed dosing 4